ESR1 and breast cancer: Furthermore, in a PDX model derived from an ER+/HER2− breast cancer patient who progressed after multiple prior lines of chemotherapy and ET (including CDK4/6i palbociclib plus letrozole), ISM5043 as monotherapy greatly inhibited tumor growth.